期刊文献+

磷脂酰肌醇3-激酶/蛋白激酶B信号通路对CD40介导胃癌细胞侵袭与转移的研究 被引量:1

Blocking PI3K/Akt signaling pathway strengthened the suppression of invasion and migration by CD40 in gastric cancer cells
原文传递
导出
摘要 目的 探讨可溶性CD40配体(sCD40L)联合磷脂酰肌醇3-激酶/蛋白激酶B(P13K/Akt)信号通路特异性阻断剂LY294002对胃癌AGS细胞体外增殖及侵袭、转移的影响;初步探讨其可能的作用机制.方法 将细胞分成对照组(仅加入含10%胎牛血清的RPMI 1640培养液)、LY294002组(20μmol/L)、sCD40L组(2μg/ml)和LY294002+sCD40L组.四甲基偶氮唑盐法检测不同浓度sCD401,及联合LY294002对细胞增殖的影响;Transwell实验和划痕实验分析细胞侵袭、转移能力的改变;Western印迹检测细胞P13K、p-Akt、血管内皮生长因子(VEGF)蛋白表达的变化.结果 LY294002作用后细胞生存率为65.7%,sCD40L作用后为70.1%,LY294002+sCD40L组生存率为41.3 0A,差异有统计学意义(P〈0.05).LY294002+sCD40L组细胞的划痕愈合速度较sCD40L和LY294002组明显减慢.LY294002+sCD40L组平均每个视野的细胞数较sCD40L和LY294002组明显减少.与对照组相比,sCD40L使P13K、p-Akt、VEGF蛋白表达升高,与LY294002联合作用后,P13K,p-Akt、VEGF蛋白表达明显降低.结论 阻断P13K/Akt信号途径可显著增强sCD40L对人胃癌AGS细胞增殖及侵袭、转移的抑制作用,为胃癌的生物治疗提供一种新的方法. Objective To investigate the effects of soluble CD40 ligand combined with LY294002,a specific inhibitor of phosphatidylinositol 3-kinase,on proliferation and invasion of gastric cancer cells (AGS ) and its potential mechanisms. Methods The effect of gradient concentration of sCD40L and its combination with LY294002 on cellular proliferation was determined using MTT assay. The ability of cellular invasion and migration was evaluated by wound healing and Transwell invasion assay. The protein expression of PI3K, p-Akt and vascular endothelia growth factor (VEGF) was tested by Western blotting. Results The inhibitory effect of cellular proliferation in sCD40L, LY294002 and sCD40L + LY294002 groups was 70. 1%, 65. 7% and 41. 3%, respectively, with significant difference (P〈0. 05). And wound healing was also delayed in cells treated with sCD40L plus LY294002 when compared with those treated with sCD40L or LY294002. These results indicated that the inhibitory effect of cellular proliferation, migration and invasion was enhanced when cells were treated with sCD40L plus LY294002. The protein expression of PI3K,p-Akt and VEGF increased in cells treated with sCD40L, but reduced drastically in cells treated with sCD40L plus LY294002. Conclusion Inhibiting PI3K/Akt signaling pathway may enhance the inhibitory effect of proliferation, migration and invasion by sCD40L on AGS cells, which provide a new way for biochemical therapy of gastric cancer.
出处 《中华消化杂志》 CAS CSCD 北大核心 2010年第7期456-460,共5页 Chinese Journal of Digestion
基金 基金项目 国家自然科学基金资助项目(30872943) 苏州市社会发展项目(SS0711)
关键词 1-磷脂酰肌醇3-激酶 蛋白激酶类 胃癌 肝瘤治疗方案 1-Phosphatidylinositol 3-kinase Protein kinases Stomach neoplasms Antineoplastic protocols
  • 相关文献

参考文献15

  • 1庞雪芹,陈卫昌,李锐,岑建农.激发CD40信号对胃癌细胞株生长增殖及基因表达谱的影响[J].中华消化杂志,2007,27(11):732-735. 被引量:3
  • 2李锐,陈卫昌,刘强,柴玉海.胃癌和癌旁组织CD40表达及其生物学意义[J].肿瘤学杂志,2005,11(2):120-122. 被引量:4
  • 3Parkin DM,Pisani P,Ferlay J,et al.Global cancer statistics.CA Cancer J Clin,1999,49:33-64.
  • 4Galon J,Costes A,Sanchez-Cabo F,et al.Type,density,and location of immune cells within human colorectal tumors predict clinical outcome.Science,2006,313:1960-1964.
  • 5von Bergwelt-Baildon M,Maecker B.Schultze J,et al.CD40 activation:potential for specific immunotherapy in B-CLL.Ann Oncol,2004,15,853-857.
  • 6Iida T,Shiba H,Misawa T,et al.Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma.Cancer Sci,2008,99:2097-2103.
  • 7García Z,Kumar A,Marqués M,et al.Phosphoinositide 3-kinase controls early and late events in mammalian cell division.EMBO J,2006,25:655-661.
  • 8Xu G,Zhang W,Bertram P,et al.Pharmaeogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.Int J Oncol,2004,24:893-900.
  • 9Davies CC,Mason J,Wakelam MJ,et al.Inhibition of phosphatidylinositol 3-kinase-and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells.J Biol Chem,2004,279-1010-1019.
  • 10Tai YT,Podar K,Mitsiades N,et al.CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signalings.Blood,2003,101,2762-2769.

二级参考文献19

  • 1童彤,宋咏梅,付明,董立佳,金顺钱,吴旻,詹启敏.Gadd45表达对肿瘤细胞HCT116生长的抑制作用及其机理[J].中华医学杂志,2003,83(21):1895-1899. 被引量:4
  • 2Kooten CT, Jacques B. CD40- CD40 Ligand[J]. J Leukocyte Biology, 2000, 67: 2-17.
  • 3Barnes DM, Meyer JS, Gonzalez JG, et al. Relationship between c-erbB-2 immunoreactivity and thymidine labeling index in breast carcinoma in situ [J]. Breast Cancer Res Treat, 1991, 18:11-17.
  • 4Holub M, Zakeri SM, Lichtenberger C, et al. Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma [J]. Eur J Gastroenterol Hepatol,2003, 15:119-126.
  • 5Jang TJ. Expression of CD40 and Fas ligand in Bowen's disease, squamous cell carcinoma and basal cell carcinoma[J]. Yonsei Med J, 2002, 43:304-308.
  • 6Sabel MS, Yamada M, Kawaguchi Y, et al. CD40 expression on human lung cancer correlates with metastatic spread[J]. Cancer Immunol Immunother, 2000, 49:101-108.
  • 7Palmer DH, Hussain SA, Ganesan R, et al. CD40 expression in prostate cancer: a ptential diagnostic and therapeutic molecule[J]. Oncol Rep, 2004, 12:679-682.
  • 8Xiang Z, Yang Y, Ma X, et al. Microarray expression profiling: analysis and applications. Curr Opin Drug Discov Devel, 2003, 6:384-395.
  • 9Weigert C, Brodbeck K, Bierhaus A, et al. c-Fos-driven transcriptional activation of transforming growth factor beta-1:inhibition of high glucose-induced promoter activity by thiazolidinediones. Biochem Biophys Res Commun, 2003, 304:301-307.
  • 10Ottaiano A, Pisano C, De Chiara A. et al. CD40 activation as potential tool in malignant neoplasms. Tumori, 2002, 88:361- 366.

共引文献5

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部